Research progress of locoregional interventional therapies combined with immune checkpoint inhibitors for intermediate-advanced hepatocellular carcinoma
10.3760/cma.j.cn371439-20230428-00121
- VernacularTitle:局部介入联合免疫检查点抑制剂治疗中晚期肝癌研究进展
- Author:
Jinming TIAN
1
;
Jijin YANG
Author Information
1. 海军军医大学附属长海医院介入治疗科，上海 200433
- Keywords:
Carcinoma, hepatocellular;
Radiofrequency ablation;
Chemoembolization, therapeutic;
Immunotherapy;
Combined modality therapy
- From:
Journal of International Oncology
2023;50(10):636-640
- CountryChina
- Language:Chinese
-
Abstract:
According to the International Agency for Research on Cancer (IARC) of the World Health Organization, the number of people with primary liver cancer is predicted to exceed 1 million per year by 2025, making it a major threat to human life and health. According to "Standardization for Diagnosis and Treatment of Hepatocellular Carcinoma (2022 edition) " issued by the National Health Commission of China, locoregional interventional therapy represented by ablation and transcatheter arterial chemoembolization (TACE) has become the main treatment for unresectable intermediate-advanced hepatocellular carcinoma (HCC), in which the indications for TACE include patients with stage Ⅰb to Ⅲb HCC. Locoregional interventional therapy has been proved to have a clear immune activation effect, and with the gradual promotion of immune checkpoint inhibitors in clinical trials and applications at home and abroad, the combination therapy of locoregional intervention and immune checkpoint inhibitors has shown a more effective objective response rate, slower progression time and longer survival, bringing new hope to patients with inoperable intermediate-advanced HCC.
